{"id":"https://openalex.org/W3133677448","doi":"https://doi.org/10.1002/cpdd.925","title":"Evaluation of Pharmacokinetics, Safety, and Drug\u2010Drug Interactions of an Oral Suspension of Edaravone in Healthy Adults","display_name":"Evaluation of Pharmacokinetics, Safety, and Drug\u2010Drug Interactions of an Oral Suspension of Edaravone in Healthy Adults","publication_year":2021,"publication_date":"2021-03-11","ids":{"openalex":"https://openalex.org/W3133677448","doi":"https://doi.org/10.1002/cpdd.925","mag":"3133677448","pmid":"https://pubmed.ncbi.nlm.nih.gov/33704925","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/8518673"},"language":"en","primary_location":{"id":"doi:10.1002/cpdd.925","doi":"https://doi.org/10.1002/cpdd.925","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cpdd.925","pdf_url":null,"source":{"id":"https://openalex.org/S2764863641","display_name":"Clinical Pharmacology in Drug Development","issn_l":"2160-763X","issn":["2160-763X","2160-7648"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology in Drug Development","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1002/cpdd.925","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5021819365","display_name":"H. Shimizu","orcid":"https://orcid.org/0000-0002-4208-9790","observed_orcids":["https://orcid.org/0000-0002-4208-9790"]},"institutions":[{"id":"https://openalex.org/I4387155982","display_name":"Tanabe Pharma Corporation (Japan)","ror":"https://ror.org/038ehsm73","country_code":"JP","type":"company","lineage":["https://openalex.org/I168192097","https://openalex.org/I4387155982"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Hidetoshi Shimizu","raw_affiliation_strings":["Mitsubishi Tanabe Pharma Corporation, Chuo-ku, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mitsubishi Tanabe Pharma Corporation, Chuo-ku, Tokyo, Japan","institution_ids":["https://openalex.org/I4387155982"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112317255","display_name":"Yukiko Nishimura","orcid":"https://orcid.org/0009-0008-6793-6344","observed_orcids":["https://orcid.org/0009-0008-6793-6344"]},"institutions":[{"id":"https://openalex.org/I4387155982","display_name":"Tanabe Pharma Corporation (Japan)","ror":"https://ror.org/038ehsm73","country_code":"JP","type":"company","lineage":["https://openalex.org/I168192097","https://openalex.org/I4387155982"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yukiko Nishimura","raw_affiliation_strings":["Mitsubishi Tanabe Pharma Corporation, Chuo-ku, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mitsubishi Tanabe Pharma Corporation, Chuo-ku, Tokyo, Japan","institution_ids":["https://openalex.org/I4387155982"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042413392","display_name":"Yoichi Shiide","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387155982","display_name":"Tanabe Pharma Corporation (Japan)","ror":"https://ror.org/038ehsm73","country_code":"JP","type":"company","lineage":["https://openalex.org/I168192097","https://openalex.org/I4387155982"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yoichi Shiide","raw_affiliation_strings":["Mitsubishi Tanabe Pharma Corporation, Chuo-ku, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mitsubishi Tanabe Pharma Corporation, Chuo-ku, Tokyo, Japan","institution_ids":["https://openalex.org/I4387155982"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Hideaki Matsuda","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387155982","display_name":"Tanabe Pharma Corporation (Japan)","ror":"https://ror.org/038ehsm73","country_code":"JP","type":"company","lineage":["https://openalex.org/I168192097","https://openalex.org/I4387155982"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Hideaki Matsuda","raw_affiliation_strings":["Mitsubishi Tanabe Pharma Corporation, Chuo-ku, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mitsubishi Tanabe Pharma Corporation, Chuo-ku, Tokyo, Japan","institution_ids":["https://openalex.org/I4387155982"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112193029","display_name":"Makoto Akimoto","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387155982","display_name":"Tanabe Pharma Corporation (Japan)","ror":"https://ror.org/038ehsm73","country_code":"JP","type":"company","lineage":["https://openalex.org/I168192097","https://openalex.org/I4387155982"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Makoto Akimoto","raw_affiliation_strings":["Mitsubishi Tanabe Pharma Corporation, Chuo-ku, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mitsubishi Tanabe Pharma Corporation, Chuo-ku, Tokyo, Japan","institution_ids":["https://openalex.org/I4387155982"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047488468","display_name":"Munetomo Matsuda","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387155982","display_name":"Tanabe Pharma Corporation (Japan)","ror":"https://ror.org/038ehsm73","country_code":"JP","type":"company","lineage":["https://openalex.org/I168192097","https://openalex.org/I4387155982"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Munetomo Matsuda","raw_affiliation_strings":["Mitsubishi Tanabe Pharma Corporation, Chuo-ku, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mitsubishi Tanabe Pharma Corporation, Chuo-ku, Tokyo, Japan","institution_ids":["https://openalex.org/I4387155982"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027981078","display_name":"Yoshinobu Nakamaru","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387155982","display_name":"Tanabe Pharma Corporation (Japan)","ror":"https://ror.org/038ehsm73","country_code":"JP","type":"company","lineage":["https://openalex.org/I168192097","https://openalex.org/I4387155982"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yoshinobu Nakamaru","raw_affiliation_strings":["Mitsubishi Tanabe Pharma Corporation, Chuo-ku, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mitsubishi Tanabe Pharma Corporation, Chuo-ku, Tokyo, Japan","institution_ids":["https://openalex.org/I4387155982"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067268545","display_name":"Yuichiro Kato","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387155982","display_name":"Tanabe Pharma Corporation (Japan)","ror":"https://ror.org/038ehsm73","country_code":"JP","type":"company","lineage":["https://openalex.org/I168192097","https://openalex.org/I4387155982"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yuichiro Kato","raw_affiliation_strings":["Mitsubishi Tanabe Pharma Corporation, Chuo-ku, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mitsubishi Tanabe Pharma Corporation, Chuo-ku, Tokyo, Japan","institution_ids":["https://openalex.org/I4387155982"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5110079549","display_name":"Kazuoki Kondo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387155982","display_name":"Tanabe Pharma Corporation (Japan)","ror":"https://ror.org/038ehsm73","country_code":"JP","type":"company","lineage":["https://openalex.org/I168192097","https://openalex.org/I4387155982"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Kazuoki Kondo","raw_affiliation_strings":["Mitsubishi Tanabe Pharma Corporation, Chuo-ku, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mitsubishi Tanabe Pharma Corporation, Chuo-ku, Tokyo, Japan","institution_ids":["https://openalex.org/I4387155982"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5021819365"],"corresponding_institution_ids":["https://openalex.org/I4387155982"],"apc_list":{"value":3300,"currency":"USD","value_usd":3300},"apc_paid":{"value":3300,"currency":"USD","value_usd":3300},"fwci":2.788,"has_fulltext":true,"cited_by_count":36,"citation_normalized_percentile":{"value":0.92048485,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":92,"max":99},"biblio":{"volume":"10","issue":"10","first_page":"1174","last_page":"1187"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10855","display_name":"Amyotrophic Lateral Sclerosis Research","score":0.9574999809265137,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10855","display_name":"Amyotrophic Lateral Sclerosis Research","score":0.9574999809265137,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.014000000432133675,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.007699999958276749,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/edaravone","display_name":"edaravone","score":0.9990000128746033},{"id":"https://openalex.org/keywords/oral-suspension","display_name":"oral suspension","score":0.9120000004768372},{"id":"https://openalex.org/keywords/amyotrophic-lateral-sclerosis","display_name":"amyotrophic lateral sclerosis","score":0.9190000295639038},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9279999732971191},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.9449999928474426},{"id":"https://openalex.org/keywords/bioequivalence","display_name":"bioequivalence","score":0.9380000233650208},{"id":"https://openalex.org/keywords/absolute-bioavailability","display_name":"absolute bioavailability","score":0.7129999995231628},{"id":"https://openalex.org/keywords/rosuvastatin","display_name":"rosuvastatin","score":0.8610000014305115},{"id":"https://openalex.org/keywords/sildenafil","display_name":"sildenafil","score":1.0},{"id":"https://openalex.org/keywords/furosemide","display_name":"furosemide","score":1.0},{"id":"https://openalex.org/keywords/oral-formulations","display_name":"oral dosage forms","score":0.49900001287460327},{"id":"https://openalex.org/keywords/single-ascending-dose","display_name":"single ascending dose","score":0.6899999976158142},{"id":"https://openalex.org/keywords/repeated-dosing","display_name":"repeated dosing","score":0.7570000290870667}],"concepts":[{"id":"https://openalex.org/C2779554857","wikidata":"https://www.wikidata.org/wiki/Q335099","display_name":"Edaravone","level":2,"score":0.9769660234451294},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8482844829559326},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.8083237409591675},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6980326175689697},{"id":"https://openalex.org/C181389837","wikidata":"https://www.wikidata.org/wiki/Q461809","display_name":"Bioavailability","level":2,"score":0.5654006600379944},{"id":"https://openalex.org/C22979827","wikidata":"https://www.wikidata.org/wiki/Q5137311","display_name":"Cmax","level":3,"score":0.5456576347351074},{"id":"https://openalex.org/C42404028","wikidata":"https://www.wikidata.org/wiki/Q864940","display_name":"Bioequivalence","level":3,"score":0.529782772064209},{"id":"https://openalex.org/C2777056448","wikidata":"https://www.wikidata.org/wiki/Q285166","display_name":"Oral administration","level":2,"score":0.49723079800605774},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.43401989340782166},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000077553","descriptor_name":"Edaravone","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000077553","descriptor_name":"Edaravone","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004347","descriptor_name":"Drug Interactions","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013535","descriptor_name":"Suspensions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016037","descriptor_name":"Single-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016166","descriptor_name":"Free Radical Scavengers","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D016166","descriptor_name":"Free Radical Scavengers","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D044465","descriptor_name":"White People","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D044466","descriptor_name":"Asian People","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D064368","descriptor_name":"Healthy Volunteers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1002/cpdd.925","doi":"https://doi.org/10.1002/cpdd.925","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cpdd.925","pdf_url":null,"source":{"id":"https://openalex.org/S2764863641","display_name":"Clinical Pharmacology in Drug Development","issn_l":"2160-763X","issn":["2160-763X","2160-7648"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology in Drug Development","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:8518673","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8518673/","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8518673/pdf/","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clin Pharmacol Drug Dev","raw_type":"Text"},{"id":"pmid:33704925","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/33704925","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical pharmacology in drug development","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":{"id":"doi:10.1002/cpdd.925","doi":"https://doi.org/10.1002/cpdd.925","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cpdd.925","pdf_url":null,"source":{"id":"https://openalex.org/S2764863641","display_name":"Clinical Pharmacology in Drug Development","issn_l":"2160-763X","issn":["2160-763X","2160-7648"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology in Drug Development","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320327566","display_name":"Mitsubishi Tanabe Pharma Corporation","ror":"https://ror.org/038ehsm73"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3133677448.pdf","grobid_xml":"https://content.openalex.org/works/W3133677448.grobid-xml"},"referenced_works_count":24,"referenced_works":["https://openalex.org/W1985410301","https://openalex.org/W2067861363","https://openalex.org/W2115763439","https://openalex.org/W2128167427","https://openalex.org/W2324916026","https://openalex.org/W2398498214","https://openalex.org/W2416750449","https://openalex.org/W2616124858","https://openalex.org/W2750922690","https://openalex.org/W2751686962","https://openalex.org/W2751841726","https://openalex.org/W2752136277","https://openalex.org/W2753425250","https://openalex.org/W2753856617","https://openalex.org/W2870204682","https://openalex.org/W2989931874","https://openalex.org/W3034439772","https://openalex.org/W3048405075","https://openalex.org/W3082727135","https://openalex.org/W4248098506","https://openalex.org/W4248518818","https://openalex.org/W4249220977","https://openalex.org/W4252979096","https://openalex.org/W4253006777"],"related_works":["https://openalex.org/W4389460905","https://openalex.org/W4389441845","https://openalex.org/W4388590315","https://openalex.org/W3158239800","https://openalex.org/W4308780447","https://openalex.org/W3005217423","https://openalex.org/W2753856617","https://openalex.org/W4389628258","https://openalex.org/W2800454843","https://openalex.org/W7100614023"],"abstract_inverted_index":{"Intravenous":[0],"(IV)":[1],"edaravone":[2,37,83,112,149,158,179,191,196,221,232],"is":[3,26],"approved":[4,66,216],"as":[5,223],"an":[6,243],"amyotrophic":[7],"lateral":[8],"sclerosis":[9],"(ALS)":[10],"treatment.":[11],"Because":[12],"IV":[13,70,220],"administration":[14],"places":[15],"a":[16,75,237],"burden":[17],"on":[18,177],"patients,":[19],"development":[20],"of":[21,33,36,56,68,80,88,142,148,156,168,175,218,239,246],"orally":[22,189],"administered":[23,190,235],"ALS":[24],"treatments":[25],"needed.":[27],"Therefore,":[28],"2":[29,97,101],"phase":[30],"1":[31,73],"studies":[32],"oral":[34,58,82,146,178,195,231],"formulations":[35,197],"in":[38,100,137,212],"healthy":[39],"subjects":[40],"examined":[41],"the":[42,54,57,65,69,85,106,129,165,203,215,219,230],"pharmacokinetics":[43],"(PK),":[44],"safety,":[45],"racial":[46,134],"differences,":[47],"and":[48,52,128,133,153,181,200],"drug-drug":[49],"interactions":[50],"(DDIs)":[51],"investigated":[53],"dose":[55,67,86,162,166,217,238],"formulation":[59,147,233],"considered":[60],"to":[61,64,90,170],"be":[62,227],"bioequivalent":[63],"formulation.":[71],"Study":[72,96],"was":[74,98,150,234],"placebo-controlled,":[76],"randomized,":[77],"single-blind":[78],"study":[79],"single-ascending-dose":[81],"with":[84,110,122,140,214,242],"range":[87,167],"30":[89,169],"300":[91,171],"mg":[92],"(n":[93,103],"=":[94,104],"56).":[95],"conducted":[99],"cohorts":[102],"84);":[105],"first":[107],"assessed":[108,204],"DDIs":[109],"multiple-dose":[111],"120":[113],"mg/day":[114],"given":[115],"over":[116],"5":[117],"or":[118,126],"8":[119],"days":[120],"(coadministered":[121],"single-dose":[123],"rosuvastatin,":[124],"sildenafil,":[125],"furosemide),":[127],"second":[130],"evaluated":[131],"PK":[132,138,180],"(Japanese/White)":[135],"differences":[136],"parameters":[139],"doses":[141],"100-mg":[143],"edaravone.":[144],"The":[145,194],"well":[151],"absorbed,":[152],"plasma":[154,213],"concentrations":[155],"unchanged":[157],"increased":[159],"more":[160],"than":[161],"proportionally":[163],"within":[164],"mg.":[172],"No":[173],"effect":[174],"race":[176],"no":[182],"notable":[183],"DDI":[184],"effects":[185],"possibly":[186],"caused":[187],"by":[188],"were":[192,198],"observed.":[193],"safe":[199],"tolerable":[201],"under":[202],"conditions.":[205],"Mathematical":[206],"modeling":[207],"determined":[208],"that":[209],"equivalent":[210],"exposures":[211],"formulation,":[222],"reported":[224],"previously,":[225],"could":[226],"achieved":[228],"when":[229],"at":[236],"\u2248100":[240],"mg,":[241],"absolute":[244],"bioavailability":[245],"\u224860%.":[247]},"counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":11},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":9},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":2}],"updated_date":"2026-11-11T12:16:26.678958","created_date":"2021-03-15T00:00:00"}